[Asia Economy Reporter Jang Hyowon] NanoEntek (CEO Jeong Chan-il) announced on the 19th that it will supply the male hormone point-of-care diagnostic system ‘FREND Testosterone’ (testosterone, male hormone) to Low T Centers, Inc., a leading male clinic chain in the United States, through its local subsidiary.

NanoEntek Supplies Male Hormone Point-of-Care Diagnostic System to US 'Loti Center' View original image


Low T Centers is a male clinic with over 50 branches nationwide in the U.S., specializing in comprehensive health examinations and treatments primarily for male hormone deficiency, as well as thyroid diseases, diabetes, cholesterol, hypertension, sleep apnea, and various other male diseases.


It has partnerships with various sports organizations, including the prestigious U.S. baseball team Texas Rangers, and is expanding its business by establishing a personalized and systematic treatment system for male hormone deficiency not only in middle-aged and older men but also in young men.


‘FREND Testosterone’ supplied by NanoEntek received approval from the U.S. Food and Drug Administration (FDA) in 2016 and applies an advanced platform called Lab-on-a-Chip, which integrates semiconductor design technology (MEMS) with biotechnology. Unlike other companies’ membrane (paper filter) rapid kits that provide qualitative positive or negative results, it can express numerical results more quickly and accurately with a small amount of sample.


Lab-on-a-Chip means placing a laboratory on a chip. It is a biochip created using semiconductor design technology to perform various complex laboratory experiments simultaneously on a chip the size of a fingernail. It is also called a microfluidics chip.


Demand for male hormone testing is increasing in developed countries with many chronic diseases, and in the U.S., it continues to grow based on increased interest in male health and high insurance reimbursement rates.



A NanoEntek official stated, “The efforts made in the advanced U.S. healthcare market are showing results,” and added, “Just as the performance has greatly improved since the delivery of the ADAM-rWBC automated white blood cell counter to the American Red Cross, we look forward to the future steps to target the U.S. market with the high-performance point-of-care diagnostic system FREND.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing